公司联合创始人、董事长兼首席执行官欧雷强概述业务最新进展:2025年第四季度业绩再次展现稳健执行力,公司不负众望完成了关键转折。从财务角度来看,我们兑现了所有承诺,实现了产品收入显著增长、美国公认会计原则(GAAP)盈利以及可观的现金流。百悦泽®已迅速成为全球领先的BTK抑制剂。2025年,我们的基石产品BTK抑制剂百悦泽®在美国和全球市场均位居榜首。百悦泽®与竞品之间的领先优势正在不断扩大。...
Source Link公司联合创始人、董事长兼首席执行官欧雷强概述业务最新进展:2025年第四季度业绩再次展现稳健执行力,公司不负众望完成了关键转折。从财务角度来看,我们兑现了所有承诺,实现了产品收入显著增长、美国公认会计原则(GAAP)盈利以及可观的现金流。百悦泽®已迅速成为全球领先的BTK抑制剂。2025年,我们的基石产品BTK抑制剂百悦泽®在美国和全球市场均位居榜首。百悦泽®与竞品之间的领先优势正在不断扩大。...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.